41-glu	ıfosinate ammoı	nium (0	CAS# 7718	2-82-2)											
		-													
Table	1a. Sub-lethal a	cute p	oisoning (s	single dose	: Clinica	al observ	ations (time	related)	<u>'</u>					<u> </u>	<b>'</b>
Ref	Reference (linked to full source)	Case No.	Case	Case category	Dose:	Notes (case, dose, time)	Time (exposure to sampling): h	Notes (blood	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Blood	Symptoms and signs	Treatment	Time (exposure to recovery): h
	T. I. I				400	( ) ( )				400=			# 140 at 05 B B4 N	41 OT 01 11D 11D	0.40 ( )
1	Takahashi 2000	1	60M	S, A	100	(a), (b)	1	sr	770	4265			1h:MS; 3h:CF, R, RA, N	1h:ST; 3h:HD, HP	240 (c)
		1					3	sr	295	1634					
2	Hirose 1999	2	65M	S, A	60	(d)	2	sr	440	2437			2h:MS, V; 4.5h:N	4.5h:AC, AR	312
		2				ET	5	sr	98.4	545					
		2				ET	10	sr	32.3	179					
		2				ET	12.5	sr	17	94					
		2				ET	15	sr	4.7	26					
		2				ET	17.5	sr	2.9	16					
		2				ET	20	sr	1.5	8.3					
		2				ET	30	sr	0.6	3.3					
Footn	otes [General G	lossar	y (via link)	lists definit	ions of	common	abbreviation	ns (genera	l terms, s	symptoms	and signs, to	reatment)]			1
	lufosinate ammo							``		ĺ .		1			
MW q	lufosinate base =	180.6													
)	tory of hypertens			g with glufos	inate de	veloped d	liabetes insip	idus.							
	jested 500 ml of l								w/v of an	anionic sur	actant, polyo	xyethylene al	kylether sulfate.		
(c) tra	nsferred from the	intens	ive care un	it on the 10t	h hospita	l day, and	d discharged	without an	y neurolo	gical comp	ications on th	e day 47th af	ter ingestion.		
(d) ing	ested about 300	ml of E	BASTA, con	taining 60 g	of glufos	inate ami	monium.								

Table	1b. Sub-lethal	acute p	oisoning (s	single dose)	: Clinica	al observ	ations (with	out time i	nformatio	n)					
Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose:	Notes (case, dose, time)	Time (exposure to sampling):	Notes (blood sample)	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Blood	Symptoms and signs	Treatment	Time (exposure to recovery): h
1	Shinohara 1997	1	67F	S, A		(a)			1790	9914			10h:SZ, N, RA	AR, HD, HP(2 days)	456
Footn	otes [General G	lossar	y (via link)	lists definit	ions of (	common	abbreviation	ns (genera	al terms, s	symptoms	and signs, to	reatment)]			
MW g	lufosinate ammo	nium =	198.6												
	lufosinate base =														
(a) ing	gested approxima	ately 50	0 ml of BAS	STA, containi	ing 18.5°	% glufosin	ate.								
Ref No.	2a. Lethal acut Reference (linked to full source)		Case	Case category	Dose:	Notes (case, dose, time)	ns (time relations) Time (exposure to sampling):	Notes (blood	Blood conc.: mg/l	Blood conc.: µM	Metabolite Blood conc.: mg/l	Blood	Symptoms and signs	Treatment	Time (exposure to death): h
no cas	200														
	otes [General G	lossar	v (via link)	liete definiti	ions of a	common	abbroviation	l se (aener:	al tarms	vmntome	and signs to	reatment)]			
	lufosinate ammo						abbi eviatioi	genera	(C)   (S)		ina signs, ti				
	lufosinate base :														
ivivv g	luiosiilate base -	100.0													
	I	1	1	1	1	l					1		1	1	

Table	2b. Lethal acute	e poiso	ning (sing	le dose): Cli	nical ob	servation	ns (without t	ime inforr	mation)						
Ref	Reference (linked to full source)	Case No.	Case	Case category		Notes (case,	Time (exposure to sampling): h	Notes (blood	Blood conc.:	Blood conc.: μΜ	Metabolite Blood conc.: mg/l	Blood	Symptoms and signs	Treatment	Time (exposure to death): h
no cas	es otes [General G	loccan	(via link)	liete dofinit	ione of a	common	abbroviation	e (aonora	l torme	vmntome	and signs to	roatmont\1			
	ufosinate ammo			lists delillit			abbieviatioi	is (genera	lemis, s	ymptoms	anu signs, u	eatmentj		I	
	ufosinate base =		130.0												
g.	4.004.0														
Ref	3a. Post-morter Reference (linked to full source)	n obse Case No.	Case	Case category		(case,	Time (exposure to sampling): h	(blood	conc.:	conc.:	Metabolite Blood conc.: mg/l	Blood	Symptoms and signs	Treatment	Time (exposure to death): h
no cas															
	otes [General G ufosinate ammo			lists definit	ions of (	common	appreviation	is (genera	ii terms, s	symptoms	and signs, ti	eatment)j			
)	ufosinate base =		196.0												
ww gi	diosiliate base =	100.0				1									
Table	3b. Post-morter	m obse	rvations (v	without time	informa	•	Time								
Ref	3b. Post-morter Reference (linked to full source)	Case	Case	vithout time  Case category		Notes (case,	(exposure	(blood	conc.:	conc.:	Metabolite Blood conc.: mg/l	Blood	Symptoms and signs	Treatment	Time (exposure to death): h
Ref	Reference (linked to full	Case	Case	Case	Dose:	Notes (case, dose,	(exposure to sampling):	(blood	conc.:	conc.:	Blood	Blood	Symptoms and signs	Treatment	•
Ref No.	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose:	Notes (case, dose, time)	(exposure to sampling): h	(blood sample)	conc.: mg/l	conc.: μΜ	Blood conc.: mg/l	Blood conc.: µM	Symptoms and signs	Treatment	•
Ref No. no cas	Reference (linked to full source) es otes [General G	Case No.	Case age/sex	Case category	Dose:	Notes (case, dose, time)	(exposure to sampling): h	(blood sample)	conc.: mg/l	conc.: μΜ	Blood conc.: mg/l	Blood conc.: µM	Symptoms and signs	Treatment	•
Ref No. no cas Footne MW gl	Reference (linked to full source)	Case No.	Case age/sex	Case category	Dose:	Notes (case, dose, time)	(exposure to sampling): h	(blood sample)	conc.: mg/l	conc.: μΜ	Blood conc.: mg/l	Blood conc.: µM	Symptoms and signs	Treatment	•